EquitiesIndia.com

Healthcare · Drug Manufacturers - Specialty & Generic

Dr. Reddy's Laboratories Ltd.

DRREDDY

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Key metrics

Market Cap

₹1.03 lakh cr

P/E Ratio

18.15x

P/B Ratio

3.08x

ROE

16.96%

ROCE

20.94%

Debt / Equity

0.14x

Net Margin

17.37%

Dividend Yield

65%

EPS

₹67.79

Period

FY2025

Shareholding pattern

As of Latest
Promoter: 29.45%FII: 52.07%Public: 18.48%

Deep-dive pages

Educational content — not investment adviceThis page presents publicly available information about Dr. Reddy's Laboratories Ltd. for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing here constitutes investment advice, a recommendation to buy or sell any security, or a solicitation to transact. All financial data shown is sourced from public BSE/NSE filings and is at least 90 days old. Past performance is not indicative of future results. Please consult a SEBI-registered adviser before making any investment decision.